BSE filing, NSE: ALICON. Summary written from the filing by ALFA Finder's alert engine.
Alicon Castalloy Ltd: key numbers
- Share price
- ₹870.35
- Market cap
- ₹1,428 Cr
- Revenue (annual)
- ₹1,776 Cr
- Net profit (annual)
- ₹34.44 Cr
- P/E (TTM)
- 39.1×Sector 30.9×
- Promoter holding
- 53.79%+0.00% QoQ
- FII holding
- 0.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alicon Castalloy Ltd
All →Alicon Castalloy Employee Stock Options
Alicon Castalloy's Nomination and Remuneration Committee granted 1,15,000 stock options to its CEO and an identified employee under the 2026 ESOP scheme. The options carry a minimum one-year vesting period.
Alicon Castalloy Other Announcement
Alicon Castalloy Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Alicon Castalloy Price Movement Clarification
Alicon Castalloy Limited clarified it is unaware of any specific reasons for the recent significant increase in trading volumes. The company confirms all material disclosures have been made.
Alicon Castalloy Annual General Meeting
Alicon Castalloy Limited concluded its 36th Annual General Meeting on September 28, 2026. Shareholders approved the FY26 financial statements and a final dividend of Rs. 3 per share.
Alicon Castalloy Other Announcement
KMP Vimal Gupta sold 4,900 equity shares of Alicon Castalloy Ltd in a market transaction for approximately Rs. 0.36 Crore.
- Value
- ₹0.36 Cr
Alicon Castalloy Other Announcement
KMP Vimal Gupta sold 2,200 equity shares of Alicon Castalloy Ltd for Rs.0.16 Crore through market sale. This PIT disclosure reflects a change in his holding.
- Value
- ₹0.16 Cr
Other board meeting date announcements
All →Patel Engineering Board Meeting Date
Patel Engineering has scheduled its Board meeting for November 5, 2026, to approve Q1 and H1 FY27 unaudited results. No financial figures or decisions are reported in this advance notice.
GKB Ophthalmics Board Meeting Date
GKB Ophthalmics scheduled its Board Meeting for November 12, 2026. The meeting will consider approving unaudited results for the September 30, 2026 quarter and half year.
Bombay Oxygen Investments Board Meeting Date
Board meeting scheduled for Nov 6, 2026 to approve Q1 and H1 FY27 unaudited results. Trading window closed for insiders Oct 1–Nov 8, 2026.
OCCL Board Meeting Date
OCCL Ltd has scheduled its Board meeting for 6 November 2026 to consider Q1 FY27 unaudited results and a possible interim dividend. The trading window for designated persons closed from 1 October 2026.
TCM Board Meeting Date
TCM Limited intimated a Board meeting for 06/11/2026 to approve Q2 FY27 results. The trading window will reopen 48 hours after the results declaration.
Mercury Laboratories Board Meeting Date
Mercury Laboratories scheduled its Board meeting for November 5, 2026, to approve Q2/H1 FY27 results. Trading window remains closed until 48 hours post-announcement.